Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Breast Cancer Detection Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Profiteer who wrote (13)	10/16/1998 6:11:00 PM
From: M&A West, Inc.	Respond to of 40

Corporate Profile for Lifeline BioTechnologies, dated Oct. 16, 1998 (BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. Published Date: Oct. 16, 1998 Company Name: Lifeline BioTechnologies Address: 1325 AirMotive Way, Ste 175 Reno, NV 89502 Main Telephone Number: 702/852-3222 Internet Home Page Address (URL) www.LBTI.com Chief Executive Officer: Dr. Kevin Buckman Chief Financial Officer: Mr. Jim Holmes Investor Relations Contact: M & A West Business number: 650/588-2678 Public Relations Contact: M & A West Business number: 650/588-2678 Trading Symbol/ Exchange: OTC BB:LBTI Industry: Bio Technology Market Makers: PGON, NAIB, USCT, SHRP, WIEN, PBLL, FRAN, BACH, SOLA, HILL Company description: Lifeline BioTechnologies, Inc. (Lifeline) has developed a non-invasive test for early breast cancer detection. The test is incorporated into a proprietary product called First Warning(TM). In preliminary pilot studies, First Warning(TM) demonstrated great promise in detecting formation of extremely early stage breast lesions, particularly in younger women. The product collects minute temperature changes on the surface of the breast, which is a reflection of the patient's underlying physiological activity. In early studies, these changes were considered deviations for the normal core temperature of the breast. But with the utilization of neural network analysis and sophisticated algorithms, these changes were found to have definite circadian (24 hour rhythm) characteristics. The system uncovered microscopic cancer in-situ via a monitor programmed to record data from the sensors. The 9000+ data points provide a significant profile of the breast's potential health. The patient's information is downloaded, interpreted, and the results are fed back to the patient's physician. The second product division under Lifeline BioTechnologies is a line of nutritional food supplements packaged and sold under the tradename NATURE'S CREATIONS. These supplements are marketed and directed towards people afflicted with degenerative diseases that are commonly found in the aging population. These diseases include cancer (breast, colon and prostate) cardiovascular, osteoporosis and mental alertness. --------------------------------------------------------------------------------